Tirzepatide is a dual GIP/GLP-1 receptor agonist
Daily drops become part of a morning/evening routine
Oh, Oh, Oh, Ozempic...Made My Stomach Hurt Semaglutide (the key ingredient in Ozempic and other GLP-1 drugs) has taken the health and wellness world by storm, emerging as a groundbreaking treatment for obesity and type 2 diabetes
Ivim is reported to operate in 49 states, with Mississippi being the notable exception
Whats different here is that a growing number of people are intentionally staying at sub-therapeutic doses long-term, rather than using low doses as a stepping stone to higher ones
By activating both GIP and GLP-1 receptors, tirzepatide enhances glucose-dependent insulin secretion from pancreatic beta cells, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite through central nervous system pathways